Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diagnosis of any of the following hematologic malignancies:
• * Acute myeloid leukemia (AML) meeting any of the following criteria:
• * First complete remission with high-risk karyotype
• * Translocations t(15;17) allowed only if failed first-line induction therapy OR molecular evidence of persistent disease exists
• * Translocations t(8;21) and inv(16) allowed only if failed first-line induction therapy
• * Second or subsequent complete remission
• * Minimal residual disease\*
• * Acute lymphoblastic leukemia meeting any of the following criteria:
• * Failed induction therapy and has minimal residual disease\* by salvage therapy
• * First complete remission with high-risk karyotype (e.g., t\[4;11\] or t\[9;22\])
• * Relapsed disease allowed provided a second or subsequent complete remission or minimal residual disease\* is achieved
• * Chronic myelogenous leukemia meeting any of the following criteria:
• * Persistent or relapsed disease after 1 year of imatinib mesylate therapy
• * Accelerated phase or blast crisis
• * Blast crisis allowed after reinduction chemotherapy places disease in chronic phase
• * Myelodysplastic syndromes meeting any of the following criteria:
• * Refractory to medical management
• * Cytogenetic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation)
• * Non-Hodgkin's lymphoma or Hodgkin's lymphoma meeting any of the following criteria:
• * Beyond first complete remission or failed primary induction therapy and demonstrated sensitivity to therapy during the 6 months before transplantation
• * Recurrent disease after autologous stem cell transplantation
• * Must be at least 3 months posttransplantation
• * Cyclin D1+ mantle cell lymphoma allowed after induction therapy and in first remission
• * Multiple myeloma meeting either of the following criteria:
• * Refractory or relapsed disease
• * Residual disease after autologous transplantation
• * Chronic lymphocytic leukemia (CLL) meeting all of the following criteria:
• * Peripheral blood absolute lymphocyte count greater than 5,000/mm\^3
• * Small to moderate size lymphocytes and less than 55% pro-lymphocytes, atypical lymphocytes, or lymphoblasts morphologically
• * B-cell or T-cell
• * Myeloproliferative disorders, including myelofibrosis
• * Philadelphia negative
• Availability of a HLA-A, B, and DR identical family donor OR HLA-A, B, and DR genetically matched unrelated donor
• Must meet 1 of the following criteria:
• * At least 55 years of age at time of transplantation
• * Received extensive prior therapy (i.e., more than 1 year of alkylator therapy or more than 2 different prior salvage regimens) or stem cell transplantation with myeloablative conditioning (either autologous or allogeneic)
• * Presenting with comorbid condition (e.g., abnormal cardiac, pulmonary, or renal function and/or prior life-threatening infection) that precludes eligibility for enrollment in allogeneic transplantation protocols with full ablation conditioning
• No active CNS disease NOTE: \*Defined as having no circulating blasts, absolute neutrophil count greater than 1,000/mm3 and less than 10% blasts in bone marrow at least 3 weeks after last systemic chemotherapy
• PATIENT CHARACTERISTICS:
• Age
• See Disease Characteristics
• Over 18
• Performance status
• ECOG 0-2
• Life expectancy
• At least 3 months
• Hematopoietic
• See Disease Characteristics
• Hepatic
• Bilirubin no greater than 2.0 mg/dL
• ALT/AST no greater than 4 times normal
• Renal
• See Disease Characteristics
• Creatinine less than 2.0 mg/dL OR
• Creatinine clearance at least 50 mL/min
• Cardiovascular
• See Disease Characteristics
• Normal cardiac function by echocardiogram or radionuclide scan
• Shortening fraction or ejection fraction at least 40% of normal
• Pulmonary
• See Disease Characteristics
• DLCO at least 60%
• FEV\_1 greater than 50% of predicted
• Pulse oximetry greater than 85%
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No uncontrolled active infection
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• At least 2 weeks since prior biologic response modifiers, signal transduction inhibitors, or monoclonal antibodies
• Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior systemic conventional chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• Not specified
• Surgery
• Not specified
• Other
• Recovered from prior therapy
• No concurrent sun block/sunscreen or any cosmetic that may act as a sunscreen (e.g., lotion with SPF) on the days of scheduled ultraviolet-B light therapy